Korro Bio announced one oral and two poster presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society, taking place from October 6-9, 2024. Venkat Krishnamurthy, Ph.D., Senior Vice President, Head of Platform, will deliver an oral presentation on KRRO-110. KRRO-110 is the company’s first development candidate for Alpha-1 Antitrypsin Deficiency (AATD).
The oral presentation is titled "KRRO-110, an RNA Editing Oligonucleotide For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD)" and is scheduled for Monday, October 7. The poster presentations include "Purification of Human ADAR Enables Evaluation of Oligo-Directed RNA Editing in a Cell-Free Environment that Predicts In Vivo Activity" and "Using ADAR1 chimeric eCLIP to understand the on-target and off-target behaviors of RNA editing oligonucleotides."
These presentations highlight Korro Bio's scientific advancements and the potential of its proprietary RNA editing platform, OPERA. The dissemination of data at a scientific conference contributes to the validation and visibility of the company's technology within the research community.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.